ContractUnderwriting Agreement • May 2nd, 2022 • PepGen Inc. • Pharmaceutical preparations • New York
PEPGEN INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTIndemnification Agreement • May 2nd, 2022 • PepGen Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between PepGen Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
PepGen Inc. (a Delaware corporation) 7,530,000 Shares of Common Stock UNDERWRITING AGREEMENTPepGen Inc. • February 7th, 2024 • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2024 • PepGen Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between PepGen Inc. (the “Company”), and Mary Beth DeLena and is effective as January 15th, 2024 (the “Effective Date”).
STIFEL NICOLAUS MASTER FORM ATM SALES AGREEMENT PEPGEN INC. Common Stock ($0.0001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENTSales Agreement • August 8th, 2023 • PepGen Inc. • Pharmaceutical preparations • New York
PepGen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), as sales agent and/or principal (“Agent”), shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), having an aggregate offering price of up to $100.0 million on the terms set forth in Section 2 of this At-The-Market Equity Offering Sales Agreement (this “Agreement”). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a “Terms Agreement”) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.
DATED January 1, 2022 Agreement for novation of contract among Continuing Parties and Outgoing Party and Incoming PartyPepGen Inc. • August 8th, 2023 • Pharmaceutical preparations
FIRST AMENDMENT TO LEASELease • May 11th, 2023 • PepGen Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 14th day of January, 2021, by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company (“Landlord”), and PEPGEN, INC., a Delaware corporation (“Tenant”).
SECOND AMENDMENT TO LEASELease • May 11th, 2023 • PepGen Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENTTO LEASE (this “Amendment”) is entered into as of this 27th day of March 2023, by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company (“Landlord”), and PEPGEN, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO LICENCE OF TECHNOLOGY AGREEMENTLicence of Technology Agreement • August 8th, 2023 • PepGen Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Agreement (this “Amendment”), effective as of 12th February 2021 (the “Amendment Effective Date”), is made by and between Oxford University Innovation Limited (Company Registration No. 2199542) whose registered office is a University Offices, Wellington Square, Oxford OX1 2JD, England (“OUI”); Medical Research Council, as part of United Kingdom Research and Innovation (also known as UK Research and Innovation) a body corporate established pursuant to section 91 of the Higher Education and Research Act 2017 whose address is Polaris House, North Star Avenue, Swindon SN2 1FL, United Kingdom (“MRC”); and PepGen Limited (Company Registration No. 11170794) whose registered office is at Bioescalator, Innovation Building, The Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ (the “Licensee”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
